Multicenter, Single-Arm Exploratory Phase I Clinical Study on the Safety and Efficacy of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Participants With Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
Multicenter, Single-Arm Exploratory Phase I Clinical Study on the Safety and Efficacy of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Participants With Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma is a PHASE1 clinical asset sponsored by Institute of Hematology & Blood Diseases Hospital, China in DLBCL, CLL, FL, MCL, WM, MZL. SEO and diligence focus: BAFF-R CAR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: DLBCL
Modality: cell therapy
Target: BAFF-R CAR-T
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: BAFF-R CAR-T
View original source fields
Condition raw: DLBCL, CLL, FL, MCL, WM, MZL
Condition normalized: DLBCL, CLL, FL, MCL, WM, MZL
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: BAFF-R CAR-T
Target normalized: BAFF-R CAR-T